3-(2-氨基乙基)-1H-吲哚-5,6-二醇 | 5090-36-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 3-(2-氨基乙基)-1H-吲哚-5,6-二醇
• 英文名称: 5,6-dihydroxytryptamine
• 英文别名: 3-(2-amino-ethyl)-indole-5,6-diol；3-(2-aminoethyl)-1H-indole-5,6-diol；5,6-Dihydroxy-3-(2-amino-ethyl)-indol；5,6-Dihydroxy-tryptamin
• CAS: 5090-36-8
• 化学式: C₁₀H₁₂N₂O₂
• mdl: MFCD01741281
• 分子量: 192.217
• InChiKey: SKOKLDQYOKPCPU-UHFFFAOYSA-N

物化性质

• 沸点：
  471.9±40.0 °C(Predicted)
• 密度：
  1.421±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  82.3
• 氢给体数：
  4
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  3-(2-氨基乙基)-1H-吲哚-5,6-二醇 生成 2,7'-bi(5,6-dihydroxytryptamine)
  参考文献：
  名称：

  Goyal, R N, Indian Journal of Chemistry, Section A: Inorganic, Physical, Theoretical and Analytical, 1992, vol. 31, # 9, p. 693 - 698

  摘要：

  DOI：

文献信息

• [EN] TRICYCLIC PIPERIDINE COMPOUNDS<br/>[FR] COMPOSÉS PIPÉRIDINIQUES TRICYCLIQUES
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2016177690A1

  公开（公告）日：2016-11-10

  The present invention relates to compounds of the formula (I) wherein R1a, R1b, R2, R3, (R4)n and ring (A) are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), to methods for the preparation of such compounds of formula (I), and especially to their use as TPH modulators.

  本发明涉及式(I)的化合物，其中R1a、R1b、R2、R3、(R4)n和环(A)如描述中所述，其制备方法，其药学上可接受的盐，以及作为药物的用途，含有一个或多个式(I)化合物的药物组合物，制备这种式(I)化合物的方法，特别是作为TPH调节剂的用途。
• [EN] TRICYCLIC IMIDAZOLE COMPOUNDS AS INHIBITORS OF TRYPTOPHAN HYDROXYLASE<br/>[FR] COMPOSÉS IMIDAZOLE TRICYCLIQUES COMME INHIBITEURS DE LA TRYPTOPHANE HYDROLASE
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2015075025A1

  公开（公告）日：2015-05-28

  The present invention relates to compounds of the formula (I), wherein R1a, R1b, R2, R3, and X are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), to methods for the preparation of such compounds of formula (I), and especially to their use as TPH modulators.

  本发明涉及式(I)的化合物，其中R1a、R1b、R2、R3和X如描述中所述，其制备方法，其药用盐，以及作为药物的用途，含有一个或多个式(I)化合物的药物组合物，制备这种式(I)化合物的方法，特别是它们作为TPH调节剂的用途。
• SYNTHESIS OF GROSSULARINES-1 AND ANALOGS THEREOF AND METHOD OF USE
  申请人：Horne A. David

  公开号：US20080033004A1

  公开（公告）日：2008-02-07

  In one embodiment of the present invention, a synthesis of grossularine-1 and N,N-didesmethylgrossularine-1 2 and analogs thereof based on a novel oxidative dimerization-electrocyclization sequence of 2-amino-4-(3-indolyl)imidazoles derived from oxotryptamine 3 is described.

  在本发明的一个实施例中，基于从氧基色胺3衍生的2-氨基-4-(3-吲哚基)咪唑的新型氧化二聚化-电环化序列，描述了grossularine-1和N,N-去甲基grossularine-12及其类似物的合成。
• TRICYCLIC PIPERIDINE COMPOUNDS
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：US20160272655A1

  公开（公告）日：2016-09-22

  The present invention relates to compounds of the formula (I) wherein R, R 1a , R 1b , R 2 , R 3 , and X are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), to methods for the preparation of such compounds of formula (I), and especially to their use as TPH modulators.

  本发明涉及式（I）的化合物，其中R、R1a、R1b、R2、R3和X如描述中所述，其制备方法，其药学上可接受的盐以及它们作为药物的用途，含有一个或多个式（I）化合物的药物组合物，制备这种式（I）化合物的方法，特别是它们作为TPH调节剂的用途。
• 5-Fluorouracil derivatives and processes for producing thereof
  申请人：Chisso Corporation

  公开号：EP0240352A2

  公开（公告）日：1987-10-07

  5-Fluorouracil derivatives of this invention are represented by a general formula: wherein R indicates a non-substituted or substituted alkylene group having 0-10 carbon atoms, A indicates an atomic group of -NH- and -CO-, n is 0 or 1, and Y indicates a non-substituted or substituted alkyl group having 1-10 carbon atoms, a non-substituted or substituted aryl group, a non-substituted or substituted heteroaryl group, a pyridinium ion having a halogen as a pair ion or an isocyanate group. These derivatives are useful as anticancer medicines and intermediates thereof and have lower toxicity than usual compounds. These derivatives are produced by specified six methods of this invention. Representative method is a process which comprises reacting 5-fluorouracil and an isocyanate represented by a general formula: Y - (A) n - R - NCO (VII) wherein R, A, n and Y are the same as those indicated in the formula (I).

  本发明的5-氟尿嘧啶衍生物由通式表示： 其中 R 表示具有 0-10 个碳原子的非取代或取代的亚烷基，A 表示 -NH- 和 -CO- 的原子团，n 为 0 或 1，Y 表示具有 1-10 个碳原子的非取代或取代的烷基、非取代或取代的芳基、非取代或取代的杂芳基、具有卤素作为配对离子的吡啶鎓离子或异氰酸酯基团。 这些衍生物可用作抗癌药物及其中间体，其毒性低于普通化合物。 这些衍生物是通过本发明指定的六种方法生产出来的。具有代表性的方法是将 5-氟尿嘧啶和由通式表示的异氰酸酯进行反应： Y - (A) n - R - NCO (VII) 其中 R、A、n 和 Y 与式（I）中所表示的相同。